Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection

Caroline K. Hull, A. D. Penman, C. K. Smith, P. D. Martin

Research output: Contribution to journalArticle

94 Citations (Scopus)

Abstract

An assay employing automated solid-phase extraction (SPE) followed by high-performance liquid chromatography with positive ion TurboIonspray tandem mass spectrometry (LC-MS-MS) was developed and validated for the quantification of rosuvastatin (Crestor™) in human plasma. Rosuvastatin is a hydroxy-methyl glutaryl coenzyme A reductase inhibitor currently under development by AstraZeneca. The standard curve range in human plasma was 0.1-30 ng/ml with a lower limit of quantification (LLOQ) verified at 0.1 ng/ml. Inaccuracy was less than 8% and imprecision less than ±15% at all concentration levels. There was no interference from endogenous substances. The analyte was stable in human plasma following three freeze/thaw cycles and for up to 6 months following storage at both -20 and -70°C. The assay was successfully applied to the analysis of rosuvastatin in human plasma samples derived from clinical trials, allowing the pharmacokinetics of the compound to be determined. © 2002 Elsevier Science B.V. All rights reserved.

Original languageEnglish
Pages (from-to)219-228
Number of pages10
JournalJournal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume772
Issue number2
DOIs
Publication statusPublished - 5 Jun 2002

Keywords

  • HMG-CoA reductase inhibitor
  • Rosuvastatin

Fingerprint Dive into the research topics of 'Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection'. Together they form a unique fingerprint.

  • Cite this